CONSORT Checklist: Standards for Reporting Randomized Controlled Trials
Consolidated Standards of Reporting Trials Checklist · Also known as: CONSORT, CONSORT 2010
The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
CONSORT is mandatory for all RCT manuscripts submitted to journals adopting CONSORT standards (majority of top-tier medical journals). Use when writing or reviewing RCT reports, conducting systematic reviews, appraising trial quality, or evaluating which trial design details are most frequently under-reported in your field.
Strengths & limitations
- International consensus-based standard endorsed by over 600 journals; wide adoption facilitates consistency in trial reporting across literature
- Comprehensive yet concise (25 items) format balances completeness with practicality; authors can complete checklist in reasonable time
- Item-specific guidance and explanatory paper (Schulz et al., 2010) reduce ambiguity; authors know exactly what to report
- Flow diagram (enrollment, allocation, follow-up, analysis) visually summarizes participant numbers, making data transparency immediate
- Linked to bias assessment: items directly address mechanisms of bias (allocation concealment, blinding) enabling readers to judge risk of bias independently
- CONSORT is a reporting standard, not a quality standard; a trial can follow CONSORT completely and still have methodological flaws or biases (e.g., improper randomization reported transparently is still biased)
- Mandatory inclusion of all 25 items assumes equal importance; in practice, some items (e.g., trial registration) may be less critical for bias assessment than others (e.g., allocation concealment)
- No enforcement mechanism; journal acceptance of a manuscript does not guarantee CONSORT compliance, and compliance is often incomplete even in published trials
- CONSORT is designed for parallel-group RCTs; design-specific extensions (cluster-randomized, crossover, non-inferiority trials) exist but are sometimes overlooked, leading to inappropriate checklists
- Journals with open-access or preprint policies may receive manuscripts with sparse reporting; CONSORT checklist is only as useful as journal enforcement
Frequently asked
Do I have to follow CONSORT if I am submitting to a journal that does not explicitly require it?
Highly recommended. Even journals not formally requiring CONSORT benefit from adherence; editors and reviewers expect modern RCT reporting to meet CONSORT standards. Submitting a completed CONSORT checklist strengthens your manuscript and facilitates peer review.
Which CONSORT extension should I use for my cluster-randomized trial?
Use CONSORT 2012 extension for cluster-randomized trials (Campbell et al., 2012), which adds items specific to clustering: how clusters were allocated (randomization unit), whether analysis accounted for clustering, and whether cluster-level data are reported. The standard CONSORT 2010 applies to parallel-group individually randomized trials.
Is a trial that fully complies with CONSORT guaranteed to be high-quality and free from bias?
No. CONSORT ensures transparent reporting of methods and results, enabling readers to assess bias risk. However, a trial can be fully CONSORT-compliant yet have serious methodological flaws (e.g., unblinded outcome assessment) or small sample size. Use CONSORT alongside Cochrane RoB 2 or CASP to evaluate quality.
What if my trial did not register prospectively? Can I still follow CONSORT?
Yes, but note the registration status. CONSORT Item 6 asks for trial registration number and registration date. If your trial was not registered prospectively (before enrollment began), report 'retrospective registration' with the date registered; this raises concerns about selective outcome reporting but does not prevent CONSORT compliance. Prospective registration is strongly preferred.
How detailed should I be in reporting the intervention (Item 5)?
Detailed enough that another researcher could reproduce the intervention (sufficient for replication studies). Include dose, frequency, duration, setting, delivery mode, and any tailoring by participant. If intervention is complex (e.g., behavioral), use an extension framework (e.g., TIDieR checklist—Template for Intervention Description and Replication).
Sources
- Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI: 10.1186/1745-6215-11-32 ↗
How to cite this page
ScholarGate. (2026, June 3). Consolidated Standards of Reporting Trials Checklist. ScholarGate. https://scholargate.app/en/research-methodology/consort-reporting-checklist
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- CASP RCT ChecklistResearch Methodology↔ compare
- Cochrane RoB 2.0Research Methodology↔ compare
- PRISMA ChecklistResearch Methodology↔ compare
- STROBE ChecklistResearch Methodology↔ compare